Bioidentical Hormones 101, 2nd Edition, Volume 3

Menopausal Hormone Replacement

De: Jeffrey Dach MD

Narrado por: Virtual Voice

Bioidentical Hormones 101 Second Edition (2025)

This book is a completely updated and revised second edition of Bioidentical Hormones 101 originally published in 2011.
This authoritative book represents 20 years of experience prescribing bioidentical hormone replacement in an outpatient setting and intended for both menopausal women as well as health care professionals. Bio-identical hormones used at appropriate dosages are safe, and effective for the relief of menopausal symptoms. Health benefits extend to all organ systems. Bioidentical hormone treatments are safest when used in the correct combination, much like a symphony with multiple musical instruments making beautiful music.

Why get your information about menopausal hormone replacement from newspapers and magazines when you can it directly from the medical literature. This is a groundbreaking book that translates the medical literature into plain English.

What are the benefits and adverse effects of HRT on the cardiovascular system, on the brain, on the risk for breast cancer, on the risk for all other cancers, and on the risk for blood clotting? All oral forms of estrogen are associated with blood clotting. Transdermal forms of estrogen are not associated with blood clots. Thus, transdermal estrogen is preferable to oral estrogen. The safest estrogens reduce the risk of breast cancer and are those that target ER beta, the tumor suppressor receptor, such as unsaturated B-ring steroids found in Premarin (CEE), estriol (E3), and testosterone metabolite 3-beta-diol. Exposure to pregnancy levels of hormones confers protection from breast cancer. Long-term estrogen deprivation (LTED) transforms estrogen from a growth factor to a death factor in breast cancer cells.

The exact hormone formula is important for optimal results. For example, a formula using Premarin-alone is not safe because of increased risk for endometrial cancer. Synthetic progestins such as MPA are are endocrine disrupting chemicals which increase risk of breast cancer. In 2011, Dr. Cynthia L. Bethea writes: "While the WHI trial [2002, first arm] made a valuable contribution in revealing the risks associated with conjugated equine estrogens treatment in postmenopausal women, it unfortunately generated considerable controversy in the field because it was interpreted as an indictment of postmenopausal hormone replacement, when in fact, it did not study hormone replacement at all: that would have required use of the natural hormones, estradiol and progesterone. The actions of the natural hormones are significantly different from those of Premarin and MPA."

The 2004 second arm Women's Health Initiative 18 year follow up shows the estrogen treated women (Premarin-alone) enjoy a 45 percent reduction in mortality from breast cancer. This is a paradigm shift in our thinking about hormones and breast cancer. Estrogen is breast cancer protective. In 2022, Dr. Isaac Manyonda writes: "The evidence now compels a paradigm shift from the traditional thinking that estrogen could cause breast cancer to a recognition that it actually prevents the disease, and that when the disease does occur (no preventative intervention achieves a 100% preventative effect), it is often picked up early and mortality is reduced by up to 44%."

There is no need for menopausal women to fear hormone replacement and suffer needlessly with menopausal symptoms of hot flashes night sweats, brain fog, insomnia, osteoarthritis, osteoporosis, coronary artery disease and dementia. We will show you routine bioidentical HRT formulas we have been using for 20 years. These are safe and effective containing estradiol, estriol, progesterone, and testosterone in the correct dosage, and route of delivery.

Author Information:
Jeffrey Dach MD
7450 Griffin Road, Suite 180/190
Davie, Fl 33314
954-792-4663
website: https://jeffreydachmd.com/
Copyright © 2025 Jeffrey Dach MD - All Rights Reserved